Effects of Lemon Verbena Extract Supplementation in Sub-ADHD Children

Sponsor
Northumbria University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05476549
Collaborator
Finzelberg GmbH (Other)
150
1
2
6.3
23.9

Study Details

Study Description

Brief Summary

The aim of this study is to investigate the effects of 15 mg/kg lemon verbena, in comparison to placebo, on the attention deficit hyperactivity disorder (ADHD) type behaviour and cognitive function of children who do not have a diagnosis of ADHD, but who exhibit high scores (highest tertile) on ADHD behaviour parameters. Multiple aspects of mood will also be assessed.

The proposed randomised, double-blind, placebo-controlled, parallel groups design methodology will assess the psychological effects of 15 mg/kg lemon verbena extract and a matched placebo prior to and after 4 and 8 weeks of supplementation. The trial will utilise the COMPASS cognitive assessment system (Northumbria University) and a range of mood measures during laboratory testing visits.

Parents and children will also take part in a concomitant smartphone study, comprising the collection of the parent's assessment of the child's behaviour/cognitive function and the child's self-report of the same, plus their mood. These assessments will take place on Days -1, 14, 28, 42 and 56.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Lemon verbena
  • Dietary Supplement: Placebo
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
Effects of Lemon Verbena Extract Supplementation on Behaviour Mood and Cognitive Function in Sub-ADHD Children
Anticipated Study Start Date :
Jul 24, 2022
Anticipated Primary Completion Date :
Jan 31, 2023
Anticipated Study Completion Date :
Jan 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Lemon verbena

Dietary Supplement: Lemon verbena
Lemon verbena supplement administered at an estimated daily dose of 15mg/kg

Placebo Comparator: Placebo

Dietary Supplement: Placebo
Placebo supplement containing carrier material only

Outcome Measures

Primary Outcome Measures

  1. Change in Conners 3 score from baseline to 8 weeks, parent rating [Baseline to 8 weeks]

  2. Change in Conners 3 score from baseline to 8 weeks, child rating [Baseline to 8 weeks]

  3. Change in total mood disturbance from baseline to 8 weeks [Baseline to 8 weeks]

    Profile of mood states questionnaire

  4. Change in depression-dejection from baseline to 8 weeks [Baseline to 8 weeks]

    Profile of mood states questionnaire

  5. Change in tension-anxiety from baseline to 8 weeks [Baseline to 8 weeks]

    Profile of mood states questionnaire

  6. Change in anger-hostility from baseline to 8 weeks [Baseline to 8 weeks]

    Profile of mood states questionnaire

  7. Change in confusion-bewilderment from baseline to 8 weeks [Baseline to 8 weeks]

    Profile of mood states questionnaire

  8. Change in vigour-activity from baseline to 8 weeks [Baseline to 8 weeks]

    Profile of mood states questionnaire

  9. Change in fatigue-inertia from baseline to 8 weeks [Baseline to 8 weeks]

    Profile of mood states questionnaire

  10. Change in systolic blood pressure from baseline to 8 weeks [Baseline to 8 weeks]

    Systolic blood pressure (mmHg)

  11. Change in diastolic blood pressure from baseline to 8 weeks [Baseline to 8 weeks]

    Diastolic blood pressure (mmHg)

  12. Change in body temperature from baseline to 8 weeks [Baseline to 8 weeks]

    Degrees Celsius

  13. Change in RMSSD during the performance of cognitive tasks from baseline to 8 weeks [Baseline to 8 weeks]

    Root mean square of successive differences between normal heartbeats (RMSSD)

  14. Change in heart rate during the performance of cognitive tasks from baseline to 8 weeks [Baseline to 8 weeks]

    Beats per minute

  15. Change in heart rate variability index during the performance of cognitive tasks from baseline to 8 weeks [Baseline to 8 weeks]

    Heart rate variability index

  16. Change in pNN50 during the performance of cognitive tasks from baseline to 8 weeks [Baseline to 8 weeks]

    pNN50 is the mean number of times per hour in which the change in consecutive normal sinus (NN) intervals exceeds 50 milliseconds.

  17. Change in stress index during the performance of cognitive tasks from baseline to 8 weeks [Baseline to 8 weeks]

    The stress index is a measure of the ratio between the parasympathetic and sympathetic tone. intervals exceeds 50 milliseconds.

  18. Change in subjective anxiety from baseline to 8 weeks [Baseline to 8 weeks]

    State-trait anxiety inventory (STAI) total score

  19. Change in subjective perceived stress from baseline to 8 weeks [Baseline to 8 weeks]

    Perceived stress scale (PSS) total score

  20. Change in subjective mood from baseline to 8 weeks, alertness [Baseline to 8 weeks]

    Visual analogue scale composite score

  21. Change in subjective mood from baseline to 8 weeks, stress [Baseline to 8 weeks]

    Visual analogue scale composite score

  22. Change in subjective mood from baseline to 8 weeks, tranquility [Baseline to 8 weeks]

    Visual analogue scale composite score

  23. Change in speed of performance from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task composite score, milliseconds

  24. Change in accuracy of performance from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task composite score, %

  25. Change in accuracy of performance on arrow flankers task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, %

  26. Change in accuracy of performance on numeric working memory task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, %

  27. Change in accuracy of performance on Stroop task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, %

  28. Change in accuracy of performance on Corsi blocks task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, %

  29. Change in accuracy of performance on rapid visual information processing task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, %

  30. Change in accuracy of performance on peg and ball task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, number of errors

  31. Change in reaction time of performance on arrow flankers task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, reaction time in milliseconds

  32. Change in reaction time of performance on numeric working memory task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, reaction time in milliseconds

  33. Change in reaction time of performance on Stroop task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, reaction time in milliseconds

  34. Change in reaction time of performance on rapid visual information processing task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, reaction time in milliseconds

  35. Change in false alarms on rapid visual information processing task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, number of false alarms

  36. Change in completion time of peg and ball task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, time in milliseconds

  37. Change in thinking time of peg and ball task from baseline to 8 weeks [Baseline to 8 weeks]

    Cognitive task score, time in milliseconds

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Are in good health as reported by themselves and their parent/guardian

  • Are aged 8 to 17 years at the time of giving assent and parents giving consent

  • Have a sex and age-related BMI less than the 98th centile according to the local NHS guidelines

  • Are rated by their parents as having a high score (T score of ≥60) on both the Connors 3 subscales of Inattention and Hyperactivity/Impulsivity.

  • Have no current diagnosis of ADHD

  • Have no relevant food intolerances/ sensitivities/ allergies

  • Are not currently using any illicit, herbal or recreational drugs including alcohol and nicotine products

  • Are not currently taking prescription medications

  • Have not taken dietary supplements e.g. Vitamins, omega 3 fish oils etc. in the last 4 weeks

  • Do not have a diagnosed neurological condition, or learning/behavioural or neurodevelopmental differences (e.g. dyslexia, autism)

  • Do not suffer from visual (including colour blindness) impairment that cannot be corrected with glasses or lenses (that may impact task performance in the opinion of the PI).

  • Do not have any pre-existing diagnosed medical condition/illness which will impact taking part in the study

  • Consume less than 250 mg/day of caffeine.

  • Can complete all of the study assessments at the training visit

  • Are not currently participating in other clinical or nutrition intervention studies, or have in the past 4 weeks

  • Are compliant with regards to treatment consumption

  • Have not taken antibiotics within the past 4 weeks

  • Do not have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Brain, Performance, Nutrition Research Centre, Northumbria University Newcastle upon Tyne Tyne & Wear United Kingdom NE1 8ST

Sponsors and Collaborators

  • Northumbria University
  • Finzelberg GmbH

Investigators

  • Principal Investigator: Philippa Jackson, PhD, Northumbria University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Northumbria University
ClinicalTrials.gov Identifier:
NCT05476549
Other Study ID Numbers:
  • 48CD1
First Posted:
Jul 27, 2022
Last Update Posted:
Jul 27, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jul 27, 2022